The injectable typhoid vaccine is considered relevant for prophylaxis and provides active immunization to support protective defense against the disease. The primary benefit of this vaccine is supporting the prevention of Typhoid fever, a severe systemic infection caused by Salmonella Typhi. The vaccine is considered relevant for patient groups who may be part of symptomatic management in situations where patients experience increased exposure to the causative agent.

This therapeutic focus is relevant for easing the symptoms that may become intense or disruptive, such as prolonged high fever and profound malaise. The vaccine may assist with reducing the likelihood of severe outcomes associated with symptoms linked to organ-specific functional stress.

Quick Fact: Supports Management of Systemic Imbalance Risk

The vaccine supports the patient by mitigating the risk of the systemic imbalance and conditions presenting with systemic or localized discomfort associated with acute S. Typhi infection.

The vaccine is commonly used in high-risk contexts, serving as a component of pre-travel planning to endemic areas and for occupational exposure protection. It provides the benefit of protection for patient groups like international travelers and pediatric populations (ge 2 years old).

The Typhoid injection vaccine (inactivated Vi capsular polysaccharide) is regulated for use only within specific populations.

Eligibility and Contraindications

Classification	Population/Condition
Allowed Use	Adults and children 2 years of age and older.
Contraindicated	Individuals with a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis) to the active substance or any vaccine component (including trace excipients like formaldehyde or casein).
Postponement Required	Persons with a febrile or acute illness should generally delay vaccination until they recover.
Special Consideration	Use in pregnancy is generally not recommended due to limited data and should only occur if clearly needed after a formal risk/benefit assessment. Use during lactation also requires caution and a risk/benefit analysis.
Use Not Established	Children under 2 years of age are generally not eligible, as the antibody response may be inadequate.

This vaccine is for intramuscular injection only and must not be administered intravascularly. While chronic immunodeficiency conditions, such as HIV infection, do not absolutely prohibit its use, an impaired immune response may occur in persons receiving immunosuppressive treatments.

The official regulatory profile for the injectable Typhoid Vi Polysaccharide vaccine is defined by two primary domains: pharmacodynamic interference with immune function and specific procedural administration constraints.

Interaction Category	Officially Documented Information
Pharmacodynamic Interference	Co-administration with immunosuppressive treatments (including agents like systemic corticosteroids or chemotherapy) may result in reduced immunogenicity of the vaccine. Regulatory bodies officially document this pharmacodynamic effect, stating that vaccination should be postponed until the conclusion of the immunosuppressive therapy when medically feasible to maximize the intended protective response.
Co-Administration Requirements	The vaccine must not be mixed with any other medicinal product in the same syringe. If the vaccine is administered during the same session as other injectable vaccines (such as Yellow Fever, Hepatitis A, or Tetanus), official documents require the use of separate injection sites and separate syringes for each individual product.
Condition-Specific Constraint	Caution is formally required for patients with a bleeding disorder or those undergoing anticoagulant therapy. This procedural constraint exists due to a documented risk of hematoma formation that can occur following the deep intramuscular injection route.

Official labeling identifies no specific pharmacokinetic interactions involving CYP enzymes or drug transporters. Furthermore, no interactions with food, alcohol, or herbal products are documented in regulatory prescribing information for this vaccine.

The Typhoid Vi Polysaccharide vaccine mechanism is initiated by the intramuscular delivery of the purified Vi capsular polysaccharide antigen, a non-toxic component isolated from Salmonella enterica serovar Typhi. This antigen is recognized as a T-cell independent Type 2 (Ti-2) antigen by the host immune system. Within the draining lymph nodes, the antigen directly binds to and activates antigen-specific B lymphocytes via surface receptors complementary to the Vi polysaccharide structure.

This direct interaction triggers the proliferation and subsequent differentiation of these B cells into plasma cells. The plasma cells undertake the de novo synthesis and secretion of opsonizing anti-Vi antibodies, primarily of the IgG class, into the systemic circulation. Concurrently, a population of long-lived memory B cells is established. These memory cells provide the foundation for an enhanced, accelerated secondary immune response upon subsequent systemic exposure to the bacterial pathogen’s native Vi antigen. The circulating IgG antibodies mediate pathogen opsonization, promoting accelerated phagocytic clearance by macrophages.

The injectable typhoid vaccine (Typhoid Vi Polysaccharide Vaccine) is typically administered as a single intramuscular (IM) dose for primary immunization against Salmonella typhi. This vaccine is generally approved for individuals two years of age and older.

Administration and Timing

• Dose: A single dose is usually 0.5 mL of the purified Vi polysaccharide solution.
• Route: The vaccine must be given as an intramuscular injection, often into the deltoid muscle in the upper arm, or the anterolateral aspect of the thigh for younger children. It must not be administered intravenously or into the gluteal area to avoid nerve or vascular complications.
• Timing: To achieve optimal protection, the primary dose should be administered at least two weeks before the potential exposure to S. typhi.

Revaccination/Booster Doses

For individuals with repeated or continued risk of exposure, a booster dose is necessary to maintain immunity. The recommended interval for revaccination with the Vi polysaccharide vaccine is typically every two to three years after the primary dose. Consult with a healthcare professional regarding the most current and country-specific booster schedule.

Precautions

Vaccination should generally be postponed in cases of moderate or severe acute illness with fever. Healthcare providers must be informed of any history of severe allergic reactions to previous typhoid vaccine doses or any component of the current vaccine. The vaccine's effectiveness may be reduced in persons with a weakened immune system.

Research Evidence / Overview of Studies for Typhoid Vaccine, Injection

---

Evidence for Use in Preventing Typhoid Fever

Researchers have conducted studies including randomized controlled trials (RCTs) and observational settings, with research examining outcomes related to systemic or functional imbalance associated with infection. The populations evaluated generally included healthy adults and some mixed-age cohorts.

Studies examined how measured incidence rates of typhoid fever compared between groups who received the vaccine and control groups. These patterns were monitored over defined time intervals, and the evidence contributes to the broader evidence landscape regarding prevention. Research highlights changes measured during the study period, focusing on preventing the acute manifestations associated with the condition.

Despite these findings, comparative evidence between different vaccine types or regimens is limited. Results apply only to the populations studied, and the evidence quality varies across studies.

---

Evidence in Children and Adolescents

Studies have specifically evaluated in younger age groups, from young children through adolescents. Research has examined the vaccine in these populations to observe patterns related to the development of immune responses and how those responses were measured in this context.

Findings from these specific studies indicate patterns that were observed, often showing measurements related to antibody levels following vaccination. Research explored patterns related to observed outcomes compared between pediatric and adult groups.

However, data for certain groups, particularly infants and very young children, remain insufficient. Follow-up durations were often limited in these age-specific cohorts.

---

Long-term Studies and Follow-up

Research has explored the duration of the body's response after receiving the vaccine. These studies focus on monitoring the persistence of measured immune markers. The available research describes patterns related to how the measured immune markers appear to evolve or decline over time.

Crucially, long-term effects are not fully established. There is limited information for outcomes measured more than a few years post-vaccination. Certainty remains low regarding persistence of immune markers decades after the initial administration.

---

What is Still Uncertain About Typhoid Vaccine, Injection

The overall evidence landscape has several gaps and areas where certainty remains low. A key limitation is that long-term effects are not fully established beyond short-to-intermediate follow-up durations. Additionally, sample sizes were modest in many studies focusing on special populations, meaning the evidence for groups like people with underlying chronic conditions is limited. Findings across various studies were sometimes mixed, which makes it challenging to describe a single, consistent pattern of protection in every environment.

Common questions about Typhoid vaccine , injection (FAQ)

Q: What is the typhoid vaccine, injection?

A: The typhoid vaccine, injection is a prescription medication used to help prevent typhoid fever caused by the bacterium Salmonella typhi.

Q: How does the injectable typhoid vaccine work?

A: The injectable typhoid vaccine works by introducing inactivated or weakened parts of the Salmonella typhi bacteria into the body. This stimulates the immune system to produce antibodies that recognize and fight the bacteria, providing protection against the disease if exposed in the future.

Q: Who should get the typhoid vaccine injection?

A: The vaccine is typically recommended for individuals who are at increased risk of exposure to typhoid fever. This includes:

• People traveling to areas where typhoid fever is common (endemic).
• Those in close contact with a person infected with Salmonella typhi.
• People who work in laboratories handling Salmonella typhi bacteria.

Q: How many doses of the injectable typhoid vaccine are needed?

A: For the injectable vaccine, usually one dose is sufficient to provide protection. However, a booster dose may be needed every two years or more frequently if continuous exposure risk remains. Specific dosing schedules depend on the product and the individual’s risk factors.

Q: How long does the protection from the injectable typhoid vaccine last?

A: Protection typically begins about 7 to 14 days after receiving the injection. For continued protection, a booster dose is often recommended every two years for people who remain at risk of exposure.

Q: What are common side effects of the typhoid vaccine, injection?

A: Common side effects are generally mild and temporary. They may include:

• Pain, swelling, or redness at the injection site.
• Fever.
• Headache.
• General discomfort or feeling unwell (malaise).

Q: Can the typhoid vaccine be given to children?

A: Yes, the injectable typhoid vaccine can be given to children, generally starting from 2 years of age, although the specific age minimum may vary depending on the product and local health recommendations.

Q: Can the typhoid vaccine be given during pregnancy?

A: The decision to administer the vaccine during pregnancy is made on a case-by-case basis. It is usually reserved for pregnant individuals who are at a high and unavoidable risk of infection, as there is less data on its safety in this population compared to other vaccines. Consultation with a healthcare provider is essential.

Q: Is there a difference between the injected and oral typhoid vaccines?

A: Yes. The injectable vaccine contains inactivated parts of the bacteria and is given as a single shot. The oral vaccine contains weakened live bacteria and is taken as four capsules over several days. They are administered at different ages and have slightly different protection schedules and side effects. Both are effective in preventing typhoid fever.

How to Store and Dispose of Typhoid Vaccine (Injection)

The Typhoid Vi Polysaccharide Vaccine requires strict adherence to the cold chain to maintain its potency, as documented by regulatory agencies.

Storage Requirements

• Mandatory Temperature: Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
• Freezing Prohibition: Do not freeze the vaccine; freezing destroys the product, and it must be discarded if this occurs.
• Light Protection: Keep the vaccine in its original container to protect it from light.
• Child Safety: Keep the product out of the sight and reach of children.

Disposal

This is a single-use product. Unused product and all waste materials, including syringes and needles, must be disposed of according to local requirements and approved pharmaceutical waste protocols. Disposal should not be via household waste or wastewater.